Summary
Ten multiple sclerosis patients, all with a rapid deteriorating disease profile, were treated with 12 mg/m2 of the cytostatic agent mitoxantrone, administered every 3 months. This dosage is only 25% of what a patient with a solid tumour would normally receive during the same time period. In all treated patients the deterioration was stopped following the initial dosage; in four out of ten patients there was even an immediate improvement of the neurological status. Eight out of nine patients showed an improvement after 1 year as compared with their enrolment status; the other one remained stabile. In correlation with the clinical improvement, the mean P100 latencies of visual evoked potentials showed a reduction after 1 year. However, the changes identified through magnetic resonance imaging were even clearer than those seen clinically. At admission, this group of patients presented with a total of 169 gadolinium (Gd)-enhancing lesions. Only 10 lesions were enhancing in nine patients 12 months after the initiation of treatment. It appears that mitoxantrone accelerates the disappearance of Gd-enhancing lesions and prevents the development of new ones. Minimal side effects such as mild nausea and a slight faintness were evident in six patients and then for only 1–2 days.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C, Fieschi C (1990) Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 40: 591–595
Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441–446
Fidler JM, DeJoy SQ, Gibbons JJ (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137:727–732
Fidler JM, DeJoy SQ, Smith FR, Gibbons JJ (1986) Selective immonomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 136:2747–2754
Fog T, Linnemann F (1970) The course of multiple sclerosis. Acta Neurol Scand 46 [Suppl]:47–58
Gonsette RE, Demonty L (1989) Mitoxantrone: A new immunosuppressive agent in multiple sclerosis. In: Gonsette RE Delmotte P (eds) Recent advances in multiple sclerosis therapy. Elsevier, Amsterdam, pp 161–164
Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR Imaging. Radiology 169: 117–122
Gruener A, Ingenhag W, Clark J (1985) Mitoxantron —Klinische Pharmakologie, Untersuchungen und Analysen zur Verträglichkeit. Fortschr Antimikrob Antineoplast Chemother 387–399
Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29:548–555
Kappos L, Städt D, Rohrbach E, Keil W, Clauss W (1988) Time course of gadolinium enhancement in MRI of patients with multiple sclerosis: effects of corticosteroid treatment. J Neurol 235:10
Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, Compston DAS, McDonald WI (1989) Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 52:14–17
Lenzhofer R (1985) Kardiotoxizität von Mitoxantron. Fortschr Antimikrob Antineoplast Chemother 4:379–386
Lublin FD, Lavasa M, Viti C, Knobler RL (1987) Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 45:122–128
Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, Barnes D, McDonald WI (1988) Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927–939
Miller DH Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 54:683–688
Phadke JG (1990) Clinical aspects of multiple sclerosis in North-East Scotland with particular reference to its course and prognosis. Brain 113:1597–1628
Polman CH, Van der Wiel HE, Netelenbos JC, Teule GJJ, Koetsier JC (1991) A commentary on steroid treatment in multiple sclerosis. Arch Neurol 48:1011–1012
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 35:35–42
Sloboda AE, Oronsky AL, Kerwar SS (1986) Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats. Clin Immunol Immunopathol 40:236–243
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mauch, E., Kornhuber, H.H., Krapf, H. et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Nuerosci 242, 96–102 (1992). https://doi.org/10.1007/BF02191555
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02191555